Skip to Content

FUDR (floxuridine) Disease Interactions

There are 6 disease interactions with FUDR (floxuridine):

Major

Floxuridine (Includes FUDR) ↔ dihydropyrimidine deficiency

Severe Potential Hazard, High plausibility. Applies to: Enzymopathy (Unspecified)

An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP. However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU. 5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase. FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.

References

  1. "Product Information. FUDR Sterile (floxuridine)." Roche Laboratories, Nutley, NJ.
Major

Floxuridine (Includes FUDR) ↔ infections

Severe Potential Hazard, High plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases. FUDR can induce myelosuppression. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. FUDR Sterile (floxuridine)." Roche Laboratories, Nutley, NJ.
Major

Floxuridine (Includes FUDR) ↔ malnutrition

Severe Potential Hazard, Moderate plausibility. Applies to: Cachexia

Floxuridine therapy is contraindicated for patients in a poor nutritional state.

Major

Floxuridine (Includes FUDR) ↔ myelosuppression

Severe Potential Hazard, High plausibility. Applies to: Bone Marrow Depression/Low Blood Counts, Fever

The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression. FUDR induces myelosuppression at recommended dosages. Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.

References

  1. "Product Information. FUDR Sterile (floxuridine)." Roche Laboratories, Nutley, NJ.
Major

Floxuridine (Includes FUDR) ↔ stomatitis

Severe Potential Hazard, Moderate plausibility. Applies to: Peptic Ulcer, Inflammatory Bowel Disease

Floxuridine induces stomatitis within the gastrointestinal tract. Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.

References

  1. "Product Information. FUDR Sterile (floxuridine)." Roche Laboratories, Nutley, NJ.
Moderate

Floxuridine (Includes FUDR) ↔ bleeding disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Bleeding

Floxuridine (FUDR) induces myelosuppression. Therapy with FUDR should be administered cautiously in patients with bleeding tendencies. Therapy with FUDR should be promptly discontinued following bleeding from any sight. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Close clinical monitoring of hematopoietic function is recommended. Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.

References

  1. "Product Information. FUDR Sterile (floxuridine)." Roche Laboratories, Nutley, NJ.

FUDR (floxuridine) drug interactions

There are 186 drug interactions with FUDR (floxuridine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide